Duchenne muscular dystrophy families are sharing stories about Elevidys complications on social media. But they aren’t ...

Sarepta shares face pressure after a second Elevidys-linked death and analyst downgrade over safety concerns and lowered revenue prospects.

Sarepta's stock has plunged due to safety concerns with ELEVIDYS, including two deaths in non-ambulatory DMD patients and regulatory uncertainty. Despite these setbacks, ELEVIDYS remains effective ...

Sarepta Therapeutics said a second patient had died after receiving its $3.2 million gene therapy to treat Duchenne muscular ...

How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with gene therapy Elevidys (delandistrogene ...

Investing.com-- TD Cowen downgraded its rating on Sarepta Therapeutics Inc (NASDAQ: SRPT) and slashed its price target ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Shares of Sarepta Therapeutics have plunged again after the drugmaker reported a second death in connection with its gene ...

Notable research news last week included Sarepta Therapeutics reporting another death associated with a trial of its Duchenne ...

The Inflation Reduction Act includes an exemption for orphan drugs for a single indication, but experts say this is far from ...